Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Wilms Tumor 1Stomatitis 1Sarcoma, Endometrial Stromal 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adrenocortical Adenoma 1

Interventions

Sorafenib 23Bevacizumab 11Radiosurgery 6Capecitabine 6Radiofrequency Ablation 5Oxaliplatin 5Fluorouracil 5Doxorubicin 5pembrolizumab 4Sunitinib 4Erlotinib Hydrochloride 4Cisplatin 4Ramucirumab 3Radiotherapy 3Nivolumab 3Leucovorin 3Carboplatin 3tremelimumab 2spartalizumab 2perflutren 2derazantinib 2carotuximab 2Mitomycin 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Ipilimumab 2Immunohistochemistry 2Gemcitabine 2Folfox protocol 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Liver Neoplasms × High-Energy Shock Waves × Clear all
NCT00019604 2017-02-03

Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
44 enrolled 7 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡